The scope and validity of the patent will depend on how x-ray diffraction data is interpreted.
COMPASS Pathways was granted U.S. Patent No. 10,519,175 which covers COMP360, their investigational psilocybin formulation which developed and produced by COMPASS Pathways. The patent covers methods of treating drug-resistant depression by administering particular dosage forms. Those dosage forms include explicit requirements that are based on interpreting x-ray diffraction data.
Psychedelic Science Review is working to bring cutting-edge science in the field of psychedelics to the public in the most accessible, thorough and accurate way possible. Join our communities on Facebook, Twitter, LinkedIn and Instagram and share our content with your network to help us bring scientifically-backed information about psychedelics to the world.
NEW! Shop the PSR Supporter Store to show your support for psychedelic science.